Skip to main content
. 2016 Oct 19;12(10):e1005951. doi: 10.1371/journal.ppat.1005951

Fig 3. Capsule production is reduced in the TIGR4 spxB mutant.

Fig 3

Capsule production was measured in two methods. In the first, cell lysates from wild type and the spxB, lctO, and double spxB/lctO mutants in either TIGR4 (A) or D39 (B) backgrounds and the wild type and spxB mutant of the capsule swapped strain (TIGR4::D39) (C) were subjected to capsule blotting. In the second, immunoreactivity against capsule was determined using whole-cell bacterial ELISA for the TIGR4 (D), D39 (E), and TIGR4::D39 (F) strains. TIGR4R and D39 R6, acapsular variants, were included as a negative control (D, E). Capsule immunoreactivity was normalized to immunoreactivity to LytA, a cell surface protein, and then plotted as percentage of wild type. Mutants were compared to the wild type using unpaired parametric t-test; ** p = 0.01–0.001, *** p<0.001.